Washington. A potential vaccine being prepared to compete with the corona virus (Covid-19) has been found to be successful in its first trial. This vaccine has been able to generate sufficient amounts of immune response, which can neutralize this dangerous virus.
According to the study published in the journal Ebiomedicine, when the mice were given the Pittsburgh Corona Virus Vaccine in the test, it began to produce antibodies against the virus within two weeks. “We know exactly where to fight the new virus,” said Andrea Gambotto, lead researcher at the University of Pittsburgh, USA. Researchers say that this vaccine has been found successful in animal tests. In the next phase of testing, this vaccine will be tried on humans. The test is expected to begin in the next few months. If it is found to be successful, it may take more than a year for the vaccine to enter the market.
Expected to compete with Covid-19 seen in new medicine
Scientists have shown a silver lining against the Corona virus (Covid-19) in a new drug undergoing testing. This drug has been found effective in blocking the path of the virus at the cell level. Treatment of corona may be possible with the development of this drug.
The study, published in the Cell Journal, sheds new light on important aspects of SARS-Covey-2, which are the cause of Covid-19. Apart from getting detailed information about the interactions of the virus at the cell level, the study also shows how the virus infects blood vessels and kidneys. Researcher Joseph Penninger of the University of British Columbia, Canada said, “We are optimistic about the new drug being developed towards the treatment of this epidemic.”